No Detail Found!

Diagnosis and Treatment of Polycythemia Vera in Pakistan; Barriers and Possible Solutions

Author(s)
Rabab Jafry Agha Khan University Hospital,Karachi,Pakistan
Safia Mehmood Khan National Institute of Blood Disease and Bone Marrow Transplant,Karachi,Pakistan
Uzma Zaidi National Institute of Blood Disease and Bone Marrow Transplant,Karachi,Pakistan
Gul Sufaida National Institute of Blood Disease and Bone Marrow Transplant,Karachi,Pakistan
Samina Naz Mukry National Institute of Blood Disease and Bone Marrow Transplant,Karachi,Pakistan
Abstract
This review aims to highlight the challenges encountered in managing Polycythemia Vera in resource-limited settings and to suggest a cost-efective strategy for timely diagnosis and treatment. Presentation to healthcare facilities at an advanced stage due to lack of awareness and limited access to medical care, delay in the diagnosis due to inadequate healthcare infrastructure, unavailability of molecular testing in the majority of centers, and suboptimal disease management, primarily due to lack of physician awareness and expertise in handling this condition are the key factors contributing to the higher rates of complications, including thrombotic events and disease progression, ultimately leading to poorer patient prognoses in Pakistani population. This review describes and evaluates a cost-efective diagnostic and treatment approach to Polycythemia Vera to reduce the morbidity and mortality of the disorder in Pakistan. A tailored investigation plan comprising of JAK2 mutation and serum erythropoietin levels and minimal cytoreductive therapy combined with phlebotomy and anti-platelet agent can be implemented to achieve optimal management of the disease in a resource-constrained country.
Publication Details
Page(s) 268-274
Published Journal: Liaquat National Journal of Primary Care, Volume: 7, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Pakistan, Polycythemia Vera, JAK2 mutation, cytoreduction therapy, cost efective, erythropoietin levels
References
Sultan S,Irfan SM,Murad S .2016 .Clinico-epidemiological profile of patients with polycythaemia rubra vera - a five year experience from a tertiary care center. Asian Pac J Cancer Prev, 17(3) : 1531-3.
Raedler LA .2014 .Diagnosis and management of polycythemia vera: Proceedings from a multidisciplinary roundtable. Am Health Drug Benefits, 7(7 Suppl 3) : S36-47.
Vardiman JW,Thiele J,Arber DA,Brunning RD,Borowitz MJ,Porwit A .2009 .The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. -03-209262, 114(5) : 937-51.
Pardanani A,Lasho T,Finke C,Hanson C .2007 .Teferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21(9) : 1960-3.
Vannucchi A,Antonioli E,Guglielmelli P,Pardanani A,Teferi A. .2008 .Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia, 22(7) : 1299-307.
Teferi A,Rumi E,Finazzi G,Gisslinger H,Vannucchi A,Rodeghiero F .2013 .Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia, 27(9) : 1874-81.
Szuber N,Mudireddy M,Nicolosi M,Penna D,Vallapureddy RR,Lasho TL .2018 .3023 Mayo Clinic patients with myeloproliferative neoplasms:Risk-stratifiedcomparisonofsurvivalandoutcomesdata among disease subgroups. Mayo Clin Proc, 08(4) : 599-610.
Nawaz R,Zhou Z,Khalid N,Cao D,Liu G,Ren Y .2021 .Incomerelated inequality in distribution of health human resource among districts of Pakistan. BMC Health Serv Res, 21 : 1-15.
Khattak S,Ahmed S,Anwar J,Bozdar M. .2012 .Frequency of janus associated kinase 2 (V617F) mutation in patients of polycythemia vera. J Coll Physicians Surg Pak, 22(2) : 80-3.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM .2016 .The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20) : 2391-405.
Panjwani A,Burle VS,Raj R,Thomas S,Gorantla V .2023 .Secondary polycythemia and venous thromboembolism: A systematic review. F1000Res, 12 : 758.
Ip FF,di Pierro I,Brown R,Cunningham I,Handelsman DJ,Liu PY .2010 .Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol, 162(2) : 385-90.
Sung SY,Chang YC,Wu HJ,Lai HC .2022 .Polycythemia-related proliferative ischemic retinopathy managed with smoking cessation: A case report. Int J Environ Res Public Health, 19(13) : .
Haider MZ,Anwer F. Secondary,Polycythemia. StatPearls. Treasure Island F. Secondary .2025 .. StatPearls Publishing, : .
Vainchenker W,Delhommeau F,Constantinescu SN,Bernard OA .2011 .New mutations and pathogenesis of myeloproliferative neoplasms. -02-292102, 118(7) : 1723-35.
Schnittger S,Bacher U,Haferlach C,Geer T,Müller P,Mittermüller J .2009 .Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica, 94(3) : 414-8.
Akram AM,Kausar H,Chaudhary A,Khalid AM,Shahzad MM,Akhtar MW .2018 .Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan. J Cancer, 9(23) : 4341-5.
Sultan S,Irfan SM .2015 .Acquired JAK-2 V617F mutational analysis in Pakistani patients with essential thrombocythemia. Asian Pac J Cancer Prev, 16(16) : 7327-30.
Sultan S,Irfan SM,Murad S .2016 .Clinico-epidemiological profile of patients with polycythaemia rubra vera-A five year experience from a tertiary care center. Asian Pac J Cancer Prev, 17(3) : 1531-3.
Passamonti F,Rumi E,Pungolino E,Malabarba L,Bertazzoni P,Valentini M .2004 .Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 117(10) : 755-61.
Hultcrantz M,Björkholm M,Dickman PW,Landgren O,Derolf Å R,Kristinsson SY .2018 .Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: A population-based cohort study. Ann Intern Med, 168(5) : 0028-25.
Barbui T,Vannucchi AM,Carobbio A,Rumi E,Finazzi G,Gisslinger H .2017 .The efect of arterial hypertension on thrombosis in lowrisk polycythemia vera. Am J Hematol, 92(1) : E5-E6.
Landolfi R,Di Gennaro L,Barbui T,De Stefano V,Finazzi G,Marfisi R .2007 .Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109(6) : 2446-52.
Tremblay D,Mascarenhas J .2020 .Novel therapies in polycythemia vera. Curr Hematol Malig Rep, 15 : 133-40.
Usman M,Bilwani F,Kakepoto G,Adil S,Sajid R,Khurshid M. . .Polycythemia vera and idiopathic erythrocytosis: Comparison of. , : .
Finazzi G,Caruso V,Marchioli R,Capnist G,Chisesi T,Finelli C .2005 .Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105(7) : 2664-70.
Rambaldi A,Iurlo A,Vannucchi AM,Noble R,von Bubnof N,Guarini A .2020 .Safety and eficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia, 34 : 2234-2237.
Marchioli R,Finazzi G,Specchia G,Cacciola R,Cavazzina R,Cilloni D .2013 .Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med, 368(1) : 22-33.
Landolfi R,Marchioli R,Kutti J,Gisslinger H,Tognoni G,Patrono C .2004 .Eficacy and safety of low-dose aspirin in polycythemia vera. New Engl J Med, 350(2) : 114-24.
Kuriakose ET,Gjoni S,Wang YL,Baumann R,Jones AV,Cross NC .2013 .: e135. Haematologica, 98(11) : .
Ferrari A,Carobbio A,Masciulli A,Ghirardi A,Finazzi G,De Stefano V .2019 .Clinical outcomes under hydroxyurea treatment in polycythemia vera: A systematic review and meta-analysis. Haematologica, 104(12) : 2391.
Teferi A,Barbui T. .2023 .Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol, 98(9) : 1465-87.
Antonioli E,Guglielmelli P,Pieri L,Finazzi M,Rumi E,Martinelli V .2012 .Hydroxyurea-related toxicity in 3,411 patients with Ph'- negative MPN. Am J Hematol, 87(5) : 552-4.
Quintás-Cardama A,Kantarjian H,Manshouri T,Luthra R,Estrov Z,Pierce S .2009 .Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol, 23(32) : 5418-24.
Gisslinger H,Zagrijtschuk O,Buxhofer-Ausch V,Thaler J,Schloegl E,Gastl GA .2015 .Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. -04-637280, 126(15) : 1762-9.
Gisslinger H,Klade C,Georgiev P,Krochmalczyk D,GerchevaKyuchukova L,Egyed M .2020 .Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. Lancet, 3026(19) : 30236-4.
Kiladjian JJ,Winton EF,Talpaz M,Verstovsek S M .2015 .Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol, 8(4) : 391-401.
Vannucchi AM,Kiladjian JJ,Griesshammer M,Masszi T,Durrant S,Passamonti F . .Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New Engl J Med2015, 372(5) : 426-35.
Masciulli A,Ferrari A,Carobbio A,Ghirardi A,Barbui T .2020 .Ruxolitinib for the prevention of thrombosis in polycythemia vera: A systematic review and meta-analysis. Blood Adv, 4(2) : 380-6.
0

Citations

0

Downloads

44

Views